Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Chronic Migraine: Multicenter Real-World Study (China)
ChiCTR2500113290Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rimegepant in chronic migraine and migraine, sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Monthly migraine days, Freedom from pain at 2 hours and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
rimegepant
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on ChiCTR2500113290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113290.